Kiniksa director trades shares under 10b5-1 plan

Kiniksa Pharmaceuticals International, plc director Quart Barry D reported option exercises and share sales in early February 2026 under a pre-arranged trading plan.

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals International, plc director Quart Barry D reported option exercises and share sales in early February 2026 under a pre-arranged trading plan. On February 2, 3, and 4, he exercised fully vested share options at an exercise price of $15.47 per Class A Ordinary Share and sold the resulting shares in open-market transactions at weighted average prices of $45.00, $45.27, and $45.02, respectively.

The transactions were effected pursuant to a Rule 10b5-1 plan executed on September 11, 2025. After these trades, he directly beneficially owned 12,546 Class A Ordinary Shares and 2,800 share options that are fully vested and exercisable.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 9 txns

Insider Quart Barry D

Role Director

Sold 15,960 shs ($722K)

Approx. gross sale proceeds $722K

Approx. exercise cost $247K

Type	Security	Shares	Price	Value
Exercise	Share Option	2,602	$0.00	$0.00
Exercise	Class A Ordinary Share	2,602	$15.47	$40K
Sale	Class A Ordinary Share	2,602	$45.02	$117K
Exercise	Share Option	12,528	$0.00	$0.00
Exercise	Class A Ordinary Share	12,528	$15.47	$194K
Sale	Class A Ordinary Share	12,528	$45.27	$567K
Exercise	Share Option	830	$0.00	$0.00
Exercise	Class A Ordinary Share	830	$15.47	$13K
Sale	Class A Ordinary Share	830	$45.00	$37K

Holdings After Transaction: Share Option — 2,800 contracts (Direct); Class A Ordinary Share — 12,546 shares (Direct)

Footnotes (5)

1. F1. This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 11, 2025.
2. F2. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $45.00 and $45.02. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
3. F3. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $45.00 and $45.48. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
4. F4. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $45.00 and $45.05. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
5. F5. The option is fully vested and exercisable.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did KNSA director Quart Barry D report in this Form 4?

Director Quart Barry D reported exercising share options and selling Class A Ordinary Shares in February 2026. He exercised options at $15.47 per share and sold the resulting shares in open-market transactions at weighted average prices around $45 per share.

Were Quart Barry D’s KNSA share sales under a 10b5-1 trading plan?

Yes. The filing states the transactions were effected under a Rule 10b5-1 plan executed on September 11, 2025. Such plans pre-schedule trades, allowing insiders to sell shares over time according to preset instructions, reducing discretion at the trade dates.

What prices were received for the KNSA shares sold by Quart Barry D?

Shares were sold at weighted average prices of $45.00, $45.27, and $45.02 on February 2, 3, and 4, 2026. Each sale was executed in multiple broker-dealer trades within narrow price ranges around those reported averages.

How many KNSA shares does Quart Barry D own after these transactions?

After the reported transactions, Quart Barry D directly beneficially owned 12,546 Class A Ordinary Shares. This figure reflects holdings following the option exercises and related sales reported for February 2, 3, and 4, 2026 in the Form 4 tables.

What is the status of the KNSA share options held by Quart Barry D?

The filing notes the options involved have an exercise price of $15.47 per share and are fully vested and exercisable. Following the February 2026 exercises, he held 2,800 share options expiring on May 28, 2029, according to the derivative securities table.

What types of securities are covered in this KNSA Form 4 filing?

The Form 4 covers non-derivative Class A Ordinary Shares and derivative share options. It details option exercises, subsequent share issuances, and open-market sales, with separate tables for each security type and the resulting beneficial ownership positions for the reporting director.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/04/2026 - 06:24 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Quart Barry D

(Last) (First) (Middle)

C/O KINIKSA PHARMACEUTICALS INT'L, PLC

105 PICCADILLY, SECOND FLOOR

(Street)

LONDON X0 W1J 7NJ

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kiniksa Pharmaceuticals International, plc [ KNSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Share	02/02/2026		M(1)		830	A	$15.47	13,376	D
Class A Ordinary Share	02/02/2026		S(1)		830	D	$45(2)	12,546	D
Class A Ordinary Share	02/03/2026		M(1)		12,528	A	$15.47	25,074	D
Class A Ordinary Share	02/03/2026		S(1)		12,528	D	$45.27(3)	12,546	D
Class A Ordinary Share	02/04/2026		M(1)		2,602	A	$15.47	15,148	D
Class A Ordinary Share	02/04/2026		S(1)		2,602	D	$45.02(4)	12,546	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option	$15.47	02/02/2026		M(1)			830	(5)	05/28/2029	Class A Ordinary Shares	830	$0	17,930	D
Share Option	$15.47	02/03/2026		M(1)			12,528	(5)	05/28/2029	Class A Ordinary Shares	12,528	$0	5,402	D
Share Option	$15.47	02/04/2026		M(1)			2,602	(5)	05/28/2029	Class A Ordinary Shares	2,602	$0	2,800	D

Explanation of Responses:

1. This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 11, 2025.

2. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $45.00 and $45.02. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

3. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $45.00 and $45.48. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

4. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $45.00 and $45.05. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

5. The option is fully vested and exercisable.

	/s/ Douglas Barry, Attorney-in-Fact	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.